Complement and microglia mediate early synapse loss in Alzheimer mouse models
Open accessThe DOI matches its Crossref record; 32 of the 33 references it cites were found in a registry or an index; 21 of the 28 sources its claims cite were checked for support.
Abstract
Too much cleaning up: The complement system and microglia seek out and destroy unwanted cellular debris for the peripheral immune system as well as excess synapses in the developing brain. Hong et al. now show how the system may go haywire in adults early in the progression toward Alzheimer's disease (AD). Aberrant synapse loss is an early feature of Alzheimer's and correlates with cognitive decline. In mice susceptible to AD, complement was associated with synapses, and microglial function was required for synapse loss. The authors speculate that aberrant activation of this “trash disposal” system underlies AD pathology. Science , this issue p. 712
Overview
CoChat Summary
TL;DR
In Alzheimer mouse models, classical complement proteins C1q and C3 increase and localize to synapses before plaques, and blocking C1q, C3, or microglial CR3 reduces early synapse loss. Soluble Aβ oligomers drive microglial engulfment of synaptic material through a CR3-dependent pathway, suggesting reactivation of developmental synaptic pruning in early AD.
Key findings
- J20 hAPP mice showed significant hippocampal synapse loss at 3–4 months, before plaque deposition; loss occurred in CA1, CA3, and dentate gyrus at 3 months but not in striatum, and was not seen at 1 month.
- C1q was elevated in J20 brains as early as 1 month, region-specifically in hippocampus and frontal cortex, and colocalized with PSD95-positive puncta; Compound E reduced soluble Aβ and C1q deposition, while oligomeric Aβ—but not monomeric Aβ or vehicle—induced C1q deposition and synaptic colocalization.
- Oligomeric Aβ induced synapse loss within 72 h in WT mice but not in C1qa knockout mice; anti-C1q antibody ANX-M1 prevented oAβ-induced synapse loss and LTP impairment, and APP/PS1xC3 KO mice did not show the synapse loss seen in 4-month APP/PS1 hippocampus.
- Microglial CD68 increased in J20 hippocampus and after oAβ; oAβ increased internalized Homer-GFP in microglia, failed to do so in CR3 KO mice, and induced hippocampal synapse loss in WT but not CR3 KO mice.
Methods
- Mouse models included J20 hAPP, APP/PS1, C1qa KO, C3 KO, CR3 KO, and Homer-GFP mice, with WT littermates and ages including 1 month, 3–4 months, and P21.
- Synapse quantification used super-resolution structured illumination microscopy, confocal imaging, and electron microscopy with colocalized pre- and postsynaptic puncta markers including synaptophysin/PSD95, synaptotagmin/homer, and synapsin/PSD95; C1q and C3 colocalization with PSD95 was also measured.
- Interventions included Compound E, intracerebroventricular or tail vein injections of soluble Aβ oligomers, monomers, or vehicle, anti-C1q antibody ANX-M1 or IgG control, acute hippocampal slice LTP recordings, and an in vivo synaptic engulfment assay.
Limitations
- The paper states that specific synaptic C1q receptors are not yet known and that oAβ and C1q may act indirectly through cytokines such as TGFβ, microglial or astrocytic activation, or other pathways including MHCI/PirB.
- The paper states that the complement pathway may not be involved in all pathological routes to AD, including plaque-associated synapse loss, and that future studies are needed to examine plaque-associated synapse loss and other synaptopathies such as tauopathies and Huntington’s disease.
- Evident from the text: the findings are from mouse models and acute hippocampal slices, not human AD tissue or clinical trials, and the study focuses on early pre-plaque mechanisms rather than established plaque-associated neuropathology.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
16 Valid · 0 Not valid · 2 Not checked · 48 Own results and interpretations
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“C1q binds synapses in vulnerable regions undergoing synapse loss (our data here; (5, 27)).”
§ Complement and Microglia Mediate Early Synapse Loss in Alzheimer Mouse Models > Abstract
What the sources say
- Supportedcites [5] Stevens B The classical complement cascade mediates CNS synapse elimination. Cell 2007 131 1164 1178 18083105 source
The Results report C1q localized to synapses in the developing dLGN during synaptic pruning and relocalized to adult retinal synapses in early glaucoma, before significant synapse loss. The Discussion likewise places synaptic C1q relocalization before or concurrent with synapse loss in the glaucoma model. (LLM, conf=0.89)
- Not checked — no full text of the sourcecites [27] Stephan AH Barres BA Stevens B The complement system: an unexpected role in synaptic pruning during development and disease. Annu. Rev. Neurosci 2012 35 369 389 22715882 source
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“suggesting that the engulfed synapses are internalized into lysosomal compartments in a manner similar to developmental synaptic pruning (6).”
§ Complement and Microglia Mediate Early Synapse Loss in Alzheimer Mouse Models > Abstract
What the sources say
- Supportedcites [6] Schafer DP Microglia Sculpt Postnatal Neural Circuits in an Activity and Complement-Dependent Manner. Neuron 2012 74 691 705 22632727 PMC3528177 source
The Results section, “Microglia engulf RGC inputs during a period of active synaptic pruning” (page unavailable), reports that most engulfed RGC inputs colocalized with microglial lysosomal compartments. The Results section, “Microglia engulf presynaptic elements specific to RGCs” (page unavailable), also identifies an RGC presynaptic marker within microglial lysosomes, supporting the proposed similarity to developmental synaptic pruning. (LLM, conf=0.94)
hedgedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Quantification of colocalized pre- and postsynaptic puncta (synaptophysin and PSD95 (Fig. 1A); synaptotagmin and homer (figs. S1A-D)) revealed a significant loss of synapses in J20 hippocampus at 3-4 months old (mo), an age that precedes plaque deposition (11, 12).”
§ Complement and Microglia Mediate Early Synapse Loss in Alzheimer Mouse Models > Abstract
What the sources say
- Supportedcites [11] Mucke L High-Level Neuronal Expression of Abeta 1-42 in Wild-Type Human Amyloid Protein Precursor Transgenic Mice: Synaptotoxicity without Plaque Formation. Journal of Neuroscience 2000 20 4050 10818140 PMC6772621 source
The citation is attached to the statement that 3–4 months precedes plaque deposition, not to the citing authors’ synapse measurements. In “Effects of hAPP mutations on formation of amyloid plaques” (Fig. 4; page not provided), the paper assesses mice at 2–4 months and reports amyloid deposition in APP Sw,Ind mice at 5–7 months; the paper identifies J20 as an APP Sw,Ind line. (LLM, conf=0.91)
- Supportedcites [12] Hong S Dynamic Analysis of Amyloid -Protein in Behaving Mice Reveals Opposing Changes in ISF versus Parenchymal A during Age-Related Plaque Formation. Journal of Neuroscience 2011 31 15861 15869 22049429 PMC3227224 source
The citation follows the statement that 3–4 months precedes plaque deposition, rather than the citing authors’ own synapse measurements. The Results section (page unavailable) identifies approximately 3-month-old J20 mice as pre-plaque and describes 3–7-month-old mice as plaque-free. (LLM, conf=0.91)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Genome-wide association studies (GWAS) implicate microglia and complement-related pathways in AD (1).”
§ Complement and Microglia Mediate Early Synapse Loss in Alzheimer Mouse Models > Abstract
What the sources say
- Supportedcites [1] Hong S Dissing-Olesen L Stevens B New insights on the role of microglia in synaptic pruning in health and disease. Curr Opin Neurobiol 2016 doi:10.1016/j.conb.2015.12.004 PMC5479435 26745839 source
The Introduction says GWAS and integrated network studies identify immune-related AD risk pathways implicating microglia. The section on microglia–synapse dysfunction identifies GWAS variants CLU and CR1, both related to complement. Page numbers are not provided in our copy. (LLM, conf=0.93)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“C1q was also similarly increased in hippocampus of another model of AD, the APP/PS1 mice (15) (Fig. S2C).”
§ Complement and Microglia Mediate Early Synapse Loss in Alzheimer Mouse Models > Abstract
What the sources say
- Supportedcites [15] Jankowsky JL Mutant presenilins specifically elevate the levels of the 42 residue beta-amyloid peptide in vivo: evidence for augmentation of a 42-specific gamma secretase. Hum. Mol. Genet 2004 13 159 170 14645205 source
The citation identifies the APP/PS1 mouse model, while the citing document points to its own Fig. S2C for the C1q increase. Figure 2 (p. 4) describes APPswe/PS1 double-transgenic mice and shows hippocampal amyloid pathology in that model. (LLM, conf=0.88)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
48 more claims · 5 with their cited sources checked
Create a free account to see all 66 claims and every source verdict.
- It may state two separate claims as one. 11
- Probably not a substantial claim. 2
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“increasing evidence demonstrate that immune signaling may not just be a consequence of protein aggregation in the brain, but that it actually causes the buildup of aggregates at the earliest stages of the disease process.15–17”
From Role of neuroinflammation in neurodegeneration development (2023) · cites this paper as [15]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In neurodegeneration, the complement pathway is activated, and inhibiting the complement proteins C1q or C3 results in less neuroinflammation, Aβ plaques and synapse loss29,30.”
From Exercise plasma boosts memory and dampens brain inflammation via clusterin (2021) · cites this paper as [30]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Before the onset of Aβ deposition, microglia engulf synapses opsonized with the complement factors C1q and C3 upon CR3-mediated recognition of C3 (121).”
From Microglia in Alzheimer's disease (2017) · cites this paper as [121]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Lack of C1q, C3, or CR3 curbed microglia activation and synaptic loss during amyloid plaque deposition.”
From Microglia Function in the Central Nervous System During Health and Neurodegeneration (2017) · cites this paper as [139]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Inappropriate control of the classical complement cascade causes unresolvable inflammation and disease (Hong et al. , 2016; Hansen, Hanson and Sheng, 2018; Morgan, 2018).”
From Spatial Transcriptomics and In Situ Sequencing to Study Alzheimer’s Disease (2020) · cites this paper as Hong et al., 2016
Experimental — accuracy not yet measured
70 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Self-check results appear here once an independent check has confirmed them.
Cited works that were retracted
Works this paper cites that were later retracted, from the retraction notices publishers deposit. Major when the notice came out before this paper was published.
A note, not an issue: for example, a cited work that was retracted only after this paper was published, which its authors could not have known.
In the paper
“It is also plausible that oAβ and C1q may work indirectly to mediate synapse loss through cytokines such as TGFβ (7), through microglial or astrocytic activation, or through other mechanisms including MHCI/PirB, another immune pathway critical for synapse elimination in development and AD (28-30).”
Cited work 10.1038/nn.3560 · retracted 2022-01-13 · notice 10.1038/s41593-021-00877-7 · this paper published 2016-05-06
Citations
Cites
1 retracted
Bialas, A. R., & Stevens, B. (2013) · Nature Neuroscience · doi:10.1038/nn.3560 · Cited by 519 · cited 2×
“It is also plausible that oAβ and C1q may work indirectly to mediate synapse loss through cytokines such as TGFβ (7), through microglial or astrocytic activation, or through other mechanisms including MHCI/PirB, another immune pathway critical for synapse elimination in development and AD (28-30).”
Self-citationRetractedAmyloid oligomers exacerbate tau pathology in a mouse model of tauopathy
Selenica, M.-L. B., Brownlow, M., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., Gordon, M. N., & Morgan, D. (2013) · Neurodegenerative Diseases · doi:10.1159/000337230 · Cited by 10,359
Alzheimer's Disease Is a Synaptic Failure
Selkoe, D. J. (2002) · Science · doi:10.1126/science.1074069 · Cited by 4,420 · cited 1×
“Synaptic deficits occur in early AD and mild cognitively impaired patients before onset of plaques and are some of the first signs of the neuronal degenerative process (4, 23-25).”
Self-citationTerry, R. D., Masliah, E., Salmon, D. P., Butters, N., DeTeresa, R., Hill, R., Hansen, L. A., & Katzman, R. (1991) · Annals of Neurology · doi:10.1002/ana.410300410 · Cited by 4,397 · cited 1×
“The degree of region-specific synapse loss is a stronger correlate of cognitive decline in AD than counts of plaques, tangles and neuronal loss (8, 9).”
Microglia Sculpt Postnatal Neural Circuits in an Activity and Complement-Dependent Manner
Schafer, D. P., Lehrman, E. K., Kautzman, A. G., Koyama, R., Mardinly, A. R., Yamasaki, R., Ransohoff, R. M., Greenberg, M. E., Barres, B. A., & Stevens, B. (2012) · Neuron · doi:10.1016/j.neuron.2012.03.026 · Cited by 4,089
Self-citationThe Classical Complement Cascade Mediates CNS Synapse Elimination
Stevens, B., Allen, N. J., Vazquez, L. E., Howell, G. R., Christopherson, K. S., Nouri, N., Micheva, K. D., Mehalow, A. K., Huberman, A. D., Stafford, B., et al. (2007) · Cell · doi:10.1016/j.cell.2007.10.036 · Cited by 3,313 · cited 4×
“Although specific receptors for C1q at synapses are not yet known, C1q binds synapses in vulnerable regions undergoing synapse loss (our data here; (5, 27)).”
InfluentialSelf-citationIdentification of a unique TGF-β–dependent molecular and functional signature in microglia
Butovsky, O., Jedrychowski, M. P., Moore, C. S., Cialic, R., Lanser, A. J., Gabriely, G., Koeglsperger, T., Dake, B., Wu, P. M., Doykan, C. E., et al. (2014) · Nature Neuroscience · doi:10.1038/nn.3599 · Cited by 2,543 · cited 1×
“S11), indicating they are resident cells (22).”
Synapse loss in frontal cortex biopsies in Alzheimer's disease: Correlation with cognitive severity
DeKosky, S. T., & Scheff, S. W. (1990) · Annals of Neurology · doi:10.1002/ana.410270502 · Cited by 2,376 · cited 1×
“The degree of region-specific synapse loss is a stronger correlate of cognitive decline in AD than counts of plaques, tangles and neuronal loss (8, 9).”
Mucke, L., Masliah, E., Yu, G.-Q., Mallory, M., Rockenstein, E. M., Tatsuno, G., Hu, K., Kholodenko, D., Johnson-Wood, K., & McConlogue, L. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-11-04050.2000 · Cited by 1,856 · cited 3×
“S4), long before Aβ plaques deposit (11, 12), raising the question of whether C1q increase in these pre-plaque brains is dependent on soluble Aβ levels.”
Jankowsky, J. L., Fadale, D. J., Anderson, J., Xu, G. M., Gonzales, V., Jenkins, N. A., Copeland, N. G., Lee, M. K., Younkin, L. H., Wagner, S. L., et al. (2004) · Human Molecular Genetics · doi:10.1093/hmg/ddh019 · Cited by 1,575
Cited by
Items 1,401–1,500 of 3,349
Petrisko, T. J., Gómez-Arboledas, Á., & Tenner, A. J. (2021) · Advances in immunology · doi:10.1016/bs.ai.2021.09.003 · Cited by 23
Shen, L., Zhang, H., Jing, L., Gao, Y. L., Liu, X., Chen, M., Khan, N. U., Tang, X., Hong, Q., Feng, C., et al. (2022) · Molecular Neurobiology · doi:10.1007/s12035-022-02801-x · Cited by 24
Lozupone, M., Imbimbo, B. P., Balducci, C., Vecchio, F. L., Bisceglia, P., Latino, R. R., Leone, M. A., Dibello, V., Solfrizzi, V., Greco, A., et al. (2022) · Alzheimer s & Dementia · doi:10.1002/alz.12728 · Cited by 30
Microglia in motor neuron disease: Signaling evidence from last 10 years
Wang, M., Lu, K., Wang, Y., Yang, B., Zhang, C., Lu, Y., & Kang, L. (2022) · Developmental Neurobiology · doi:10.1002/dneu.22905 · Cited by 27
Manipulation of the diet–microbiota–brain axis in Alzheimer’s disease
Lee, D. D., Lee, V. M. ‐., & Hur, S. K. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.1042865 · Cited by 29
Amyloid-β in Alzheimer’s disease – front and centre after all?
Weglinski, C., & Jeans, A. F. (2023) · Neuronal Signaling · doi:10.1042/ns20220086 · Cited by 26
Tan, X.-X., Wang, J., Yao, J., Yuan, J., Dai, Y., Sun, M., Zhang, T., Yang, J., Cai, W., Qiu, L., et al. (2023) · Neuroscience Letters · doi:10.1016/j.neulet.2023.137049 · Cited by 27
Ying, J., Reboreda, A., Yoshida, M., & Brandon, M. P. (2023) · Current Biology · doi:10.1016/j.cub.2023.04.065 · Cited by 29
Lorenzini, I., Alsop, E. B., Levy, J., Gittings, L. M., Lall, D., Rabichow, B. E., Moore, S. R., Pevey, R. S., Bustos, L. M., Burciu, C., et al. (2023) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2023.1179796 · Cited by 35
Yi, Y., Chang, Y., Li, S., Zhu, J., Wu, Y., Jiang, X., Li, L., Liu, R., Ma, R., & Li, G. (2023) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2023.110685 · Cited by 28
“CR3 receptor attenuates synapse loss and protects against cognitive impairment and neurodegeneration in AD mouse models(16, 17).”
BackgroundSelf-citationPérez-Acuña, D., Shin, S. J., Rhee, K. H., Kim, S. J., & Lee, S. (2023) · Molecular Brain · doi:10.1186/s13041-023-01059-1 · Cited by 27
Meng, Q., Chao, Y., Zhang, S., Ding, X., Feng, H., Zhang, C., Liu, B., Zhu, W., Li, Y., Zhang, Q., et al. (2023) · Molecular Brain · doi:10.1186/s13041-023-01068-0 · Cited by 27
“In addition to neurotransmitters, the loss of synaptic plasticity and integrity is another important cause of cognitive dysfunction [26].”
BackgroundHealy, D., Murray, C., McAdams, C., Power, R. W., Hollier, P.-L., Lambe, J., Tortorelli, L. S., López-Rodríguez, A. B., & Cunningham, C. M. (2024) · Communications Biology · doi:10.1038/s42003-023-05662-9 · Cited by 27
“…regional and temporal overlap between loss of presynaptic terminals in the stratum radiatum of the hippocampus and microgliosis during neurodegeneration 59 and more recent studies show that microglia, via complement components C1q and C3, are actively involved in synaptic loss in models of AD 60 .”
GDE2 is essential for neuronal survival in the postnatal mammalian spinal cord
Cave, C., Park, S., Rodriguez, M., Nakamura, M., Höke, A., Pletnikov, M. V., & Sockanathan, S. (2017) · Molecular Neurodegeneration · doi:10.1186/s13024-017-0148-1 · Cited by 25
“Astrocytes, oligodendrocytes, and microglia have been identified as active components in the degeneration of neurons seen in mouse models of Amyotrophic Lateral Sclerosis (ALS) [55, 56] and Alzheimer’s Disease [57].”
BackgroundThe role of Alu-derived RNAs in Alzheimer’s and other neurodegenerative conditions
Polesskaya, O., Kananykhina, E. Y., Roy‐Engel, A. M., Nazarenko, O., Kulemzina, I. A., Baranova, A. V., Vassetzky, Y. S., & Myakishev-Rempel, M. (2018) · Medical Hypotheses · doi:10.1016/j.mehy.2018.03.008 · Cited by 25
Synapse maintenance and restoration in the retina by NGL2
Soto, F., Zhao, L., & Kerschensteiner, D. (2018) · eLife · doi:10.7554/elife.30388 · Cited by 26
“Synapse loss can long precede cell death in neurodegenerative diseases, and the ability to establish connections with mature circuits limits benefits from transplantation of stem-cell-derived neuronal replacements (Buckingham et al., 2008; Gamm et al., 2015; Hong et al., 2016; Scheff et al., 2006).”
BackgroundArakaki, X., Lee, R. Y., King, K. S., Fonteh, A. N., & Harrington, M. G. (2019) · PLoS ONE · doi:10.1371/journal.pone.0208517 · Cited by 23
The Complement Regulator Susd4 Influences Nervous-System Function and Neuronal Morphology in Mice
Zhu, H., Meissner, L. E., Byrnes, C., Tuymetova, G., Tifft, C. J., & Proia, R. L. (2020) · iScience · doi:10.1016/j.isci.2020.100957 · Cited by 24
Grovola, M. R., Paleologos, N., Wofford, K. L., Harris, J. P., Browne, K. D., Johnson, V. E., Duda, J. E., Wolf, J. A., & Cullen, D. K. (2020) · Journal of Neuroinflammation · doi:10.1186/s12974-020-1720-0 · Cited by 28
Kedia, S., Ramakrishna, P., Netrakanti, P. R., Singh, N., Sisodia, S. S., Jose, M., Kumar, S., Mahadevan, A., Ramanan, N., Nadkarni, S., et al. (2020) · iScience · doi:10.1016/j.isci.2020.101924 · Cited by 24
van der Spek, S. J. F., Gonzalez‐Lozano, M. A., Koopmans, F., Miedema, S. S. M., Paliukhovich, I., Smit, A. B., & Li, K. W. (2021) · Cells · doi:10.3390/cells10071588 · Cited by 27
Uncovering Plaque-Glia Niches in Human Alzheimer’s Disease Brains Using Spatial Transcriptomics
Avey, D. R., Ng, B., Vialle, R. A., Kearns, N. A., de Paiva Lopes, K., Iatrou, A., De Tissera, S., Vyas, H., Saunders, D. M., Flood, D. J., et al. (2024) · doi:10.1101/2024.09.05.611566 · Cited by 24
“Because inflammatory response 35 , complement cascades 36 , disturbed extracellular vesicle release 37 , and abnormal lysosome-autophagy pathways 38 have been implicated in AD pathogenesis, our results also suggest that the plaque-surrounding glia are implicated in multiple facets of AD…”
Wang, C., Li, H., Chen, C., Yao, X., Yang, C., Yu, Z., Ren, J., Ming, Y., Huang, Y., Rong, Y., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24119394 · Cited by 28
“The data were considered statistically significant at p < 0.05.”
MethodInfluentialZott, B., Nästle, L., Grienberger, C., Unger, F., Knauer, M., Wolf, C., Keskin, A. D., Feuerbach, A., Busche, M. A., Skerra, A., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-50153-y · Cited by 22
Hu, J., Ji, W.-J., Liu, G.-Y., Su, X., Zhu, J.-M., Hong, Y., Xiong, Y., Zhao, Y.-Y., Li, W., & Xie, W. D. (2025) · Journal of Neuroinflammation · doi:10.1186/s12974-025-03367-w · Cited by 31
“Microglia participate in synaptic pruning, and dysregulated pruning is associated with various brain diseases [39, 40].”
Uncovering plaque-glia niches in human Alzheimer’s disease brains using spatial transcriptomics
Avey, D. R., Ng, B., Vialle, R. A., Kearns, N. A., Lopes, K. D. P., Iatrou, A., Tissera, S. L. D., Vyas, H., Saunders, D. M., Flood, D. J., et al. (2025) · Molecular Neurodegeneration Advances · doi:10.1186/s44477-025-00002-z · Cited by 39
“Because inflammatory response [47], complement cascades [48], disturbed extracellular vesicle release [49], and abnormal lysosome-autophagy pathways [50] have been implicated in AD pathogenesis, our results also suggest that the plaque-surrounding glia are implicated in multiple facets of AD…”
Microglia in Alzheimer’s Disease
Süß, P., & Schlachetzki, J. C. M. (2020) · Current Alzheimer Research · doi:10.2174/1567205017666200212155234 · Cited by 29
Qin, T., Prins, S., Groeneveld, G. J., van Westen, G. J. P., de Vries, H. E., Wong, Y. C., Bischoff, L. J. M., & de Lange, E. C. M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21093158 · Cited by 27
Evolving Models and Tools for Microglial Studies in the Central Nervous System
Zhang, Y., & Cui, D. (2021) · Neuroscience Bulletin · doi:10.1007/s12264-021-00706-8 · Cited by 25
Beura, S. K., Panigrahi, A. R., Yadav, P., Agrawal, S., & Singh, S. K. (2021) · Molecular Neurobiology · doi:10.1007/s12035-021-02587-4 · Cited by 25
Menden, A., Hall, D., Hahn-Townsend, C., Broedlow, C. A., Joshi, U., Pearson, A., Crawford, F., Evans, J. E., Klatt, N. R., Crynen, S., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-08840-7 · Cited by 23
Taddei, R. N., Sanchez-Mico, M. V., Bonnar, O., Connors, T. R., Gaona, A., Denbow, D., Frosch, M. P., & Gómez‐Isla, T. (2022) · Acta Neuropathologica Communications · doi:10.1186/s40478-022-01370-3 · Cited by 24
Ensheathing glia promote increased lifespan and healthy brain aging
Sheng, L., Shields, E. J., Gospočić, J., Sorida, M., Ju, L., Byrns, C. N., Carranza, F. R., Berger, S. L., Bonini, N. M., & Bonasio, R. (2023) · Aging Cell · doi:10.1111/acel.13803 · Cited by 24
Human microglial models to study host–virus interactions
McMillan, R. E., Wang, E. Y., Carlin, A. F., & Coufal, N. G. (2023) · Experimental Neurology · doi:10.1016/j.expneurol.2023.114375 · Cited by 26
Scott‐Hewitt, N., Huang, Y., & Stevens, B. (2023) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.15010 · Cited by 24
Self-citationQi, F., Zuo, Z., Hu, K., Wang, R., Wu, T., Liu, H., Tang, J., Wang, Q., Xie, Y., Tan, L., et al. (2023) · Molecular Psychiatry · doi:10.1038/s41380-023-02097-w · Cited by 26
“Inhibition of neutrophil in fi ltration by wild-type serum rescues synaptic loss and microglial activation in APP/PS1 mice Synaptic loss is usually detected early in AD patients [51] and in mouse models of the disease [52].”
BackgroundLiu, Z., Dai, H., Yao, L., Chen, W., Wang, Y., Ma, L.-Y., Li, X., Lin, S., He, M., Gao, P., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-39750-5 · Cited by 27
“3d), a C1Q receptor gene that could contribute to microglial activation 24 – 26 .”
The integration site of the APP transgene in the J20 mouse model of Alzheimer’s disease
Tosh, J., Rickman, M., Rhymes, E., Norona, F. E., Clayton, E. L., Mucke, L., Isaacs, A. M., Fisher, E., & Wiseman, F. K. (2017) · Wellcome Open Research · doi:10.12688/wellcomeopenres.12237.2 · Cited by 31
Food allergy induces alteration in brain inflammatory status and cognitive impairments
Liqing, Z., Chen, L., Li, X., Li, T., Dong, Z., & Wang, Y. T. (2018) · Behavioural Brain Research · doi:10.1016/j.bbr.2018.01.011 · Cited by 24
“creased activation of microglia is observed during the pathogenesis of a number of brain disorders, such as Alzheimer's disease [31,32], Parkinson’s disease [33,34], and psychiatric disorders [35], which may contribute to some symptoms of the brain disorders.”
BackgroundMicroglia Under the Spotlight: Activity and Complement-Dependent Engulfment of Synapses
Thion, M. S., & Garel, S. (2018) · Trends in Neurosciences · doi:10.1016/j.tins.2018.03.017 · Cited by 24
Hui, C. W., Bhardwaj, S. K., Sharma, K. P., Joseph, A. T., Bisht, K., Picard, K., Tremblay, M., & Srivastava, L. K. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2018.12.007 · Cited by 27
Andrews, R. N., Dugan, G. O., Peiffer, A. M., Hawkins, G. A., Hanbury, D. B., Bourland, J. D., Hampson, R. E., Deadwyler, S. A., & Cline, J. M. (2019) · Radiation Research · doi:10.1667/rr15263.1 · Cited by 25
Xia, Z., Peng, W., Cheng, S., Zhong, B., Sheng, C., Zhang, C., Gong, W., Cheng, S., Li, J., & Wang, Z. (2017) · Oncotarget · doi:10.18632/oncotarget.17337 · Cited by 24
“Recent evidences have indicated that neuroinflammation is central for AD pathogenesis [5–7], contributing to Aβ depositions [8], neurofibrillary tangles [9], neuronal synaptic loss and cognitive dysfunction [10, 11].”
BackgroundSynaptic pruning by microglia: lessons from genetic studies in mice
de Deus, J. L., Faborode, O. S., & Nandi, S. (2024) · Developmental Neuroscience · doi:10.1159/000541379 · Cited by 23
“Using C1q − / − , C3 − / − , and Cr3 − / − mice, authors demonstrate that complement mediates early microglial phagocytic activity and hippocampal synapse loss in an amyloidosis mouse model of AD [74] (Table 2).”
Xia, E., Xu, F., Hu, C., Kumal, J. P. P., Tang, X., Mao, D., Li, Y., Wu, D., Zhang, R., Wu, S., et al. (2019) · Neuroscience · doi:10.1016/j.neuroscience.2019.08.010 · Cited by 22
Rodent Modeling of Alzheimer's Disease in Down Syndrome: In vivo and ex vivo Approaches
Farrell, C., Mumford, P., & Wiseman, F. K. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.909669 · Cited by 22
You, Y., Chen, Z., & Hu, W. (2024) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2024.108606 · Cited by 27
Complement C3aR signaling: Immune and metabolic modulation and its impact on Alzheimer's disease
Gedam, M., & Zheng, H. (2024) · European Journal of Immunology · doi:10.1002/eji.202350815 · Cited by 27
“In vivo studies have demonstrated the impact of disrupting this loop in various AD mouse models [25, 26, 50, 68–70].”
Zhang, S. Q., Wang, X., Liu, S., Hu, C. Y., & Meng, Y. (2024) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2024.09.008 · Cited by 26
Tangavelou, K., & Bhaskar, K. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252212335 · Cited by 25
“Notably, increased synaptic pruning has been shown to impair memory before A β deposition in the J20 transgenic AD mouse model [130].”
Progranulin deficiency in the brain: the interplay between neuronal and non-neuronal cells
Gawęda-Walerych, K., Aragona, V., Lodato, S., Sitek, E. J., Narożańska, E., & Buratti, E. (2025) · Translational Neurodegeneration · doi:10.1186/s40035-025-00475-8 · Cited by 23
“Aberrant or reactivated synaptic pruning precedes protein pathology in various neurodegenerative diseases [246, 250, 251].”
Qi, F., Zuo, Z., Hu, S., Xia, Y., Song, D., Kong, J., Yang, Y., Wu, Y., Wang, X., Yang, J., et al. (2018) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2018.04.003 · Cited by 21
Espericueta, V., Manughian-Peter, A. O., Bally, I., Thielens, N. M., & Fraser, D. A. (2019) · Molecular Immunology · doi:10.1016/j.molimm.2019.10.008 · Cited by 22
Oligomeric Forms of Human Amyloid-Beta(1–42) Inhibit Antigen Presentation
Gericke, C., Mallone, A., Engelhardt, B., Nitsch, R. M., & Ferretti, M. T. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01029 · Cited by 22
“While the APP-PS1 model, like all APP-transgenic mouse models, was not originally designed to address immunological questions, it has been widely used in the field to study the effect of beta-amyloid pathology on a variety of cell types, including microglia (54).”
BackgroundZhang, H., Jia, L., & Jia, J. (2020) · Frontiers in Neurology · doi:10.3389/fneur.2020.00623 · Cited by 25
“In a mouse model of early phase AD, soluble Aβ oligomers induced the engulfment of synapses to contribute to cognitive decline in a CR3 pathway-dependent manner (12).”
BackgroundDetection of molecular signatures and pathways shared by Alzheimer’s disease and type 2 diabetes
Shu, J., Li, N., Wei, W., & Zhang, L. (2021) · Gene · doi:10.1016/j.gene.2021.146070 · Cited by 31
Wang, D., Wu, Y., Pan, Y., Wang, S., Liu, G., Gao, Y., & Xu, K. (2022) · Molecular Neurobiology · doi:10.1007/s12035-022-03011-1 · Cited by 25
Emerging Roles of Cells and Molecules of Innate Immunity in Alzheimer’s Disease
Tamburini, B., Badami, G. D., Manna, M. P. L., Azgomi, M. S., Caccamo, N., & Dieli, F. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241511922 · Cited by 25
“Neutralizing antibodies against C1q or genetic C1q knockouts prevents the synapse loss seen in amyloid-bearing mice or brought on by βA injections [5].”
BackgroundInfluentialRevisiting the role of the complement system in intracerebral hemorrhage and therapeutic prospects
Li, Y., Tao, C., An, N., Liu, H., Liu, Z., Zhang, H., Sun, Y., Xing, Y., & Gao, Y. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.110744 · Cited by 28
Molecular cross-talk between long COVID-19 and Alzheimer’s disease
Pszczołowska, M., Walczak, K., Miśków, W., Antosz, K., Batko, J., Karska, J., & Leszek, J. (2024) · GeroScience · doi:10.1007/s11357-024-01096-1 · Cited by 26
“The latter issue could resemble abnormal synaptic pruning by microglia triggered by complement signaling characteristics for Alzheimer’s disease [48].”
BackgroundWerren, E. A., Peirent, E. R., Jäntti, H., Guxholli, A., Srivastava, K. R., Orenstein, N., Narayanan, V., Wiszniewski, W. K., Dawidziuk, M., Gawliński, P., et al. (2024) · Cell Death and Disease · doi:10.1038/s41419-024-06768-6 · Cited by 23
Microglia-Synapse Pathways: Promising Therapeutic Strategy for Alzheimer’s Disease
Xie, J., Wang, H., Lin, T., & Bi, B. (2017) · BioMed Research International · doi:10.1155/2017/2986460 · Cited by 22
“the brain,microglia also influence neuronal function [24, 25].”
Itoh, Y., & Voskuhl, R. R. (2017) · PLoS ONE · doi:10.1371/journal.pone.0181349 · Cited by 23
Molecular Connection Between Diabetes and Dementia
Chen, Y., Yu, Q., & Gong, C. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-981-13-3540-2_6 · Cited by 28
von Saucken, V. E., Jay, T. R., & Landreth, G. E. (2020) · Neurobiology of Disease · doi:10.1016/j.nbd.2020.105072 · Cited by 23
Zhang, J., Dong, Y., Huang, L., Xu, X., Liang, F., Soriano, S. G., Zhang, Y., & Xie, Z. (2020) · Brain Behavior & Immunity - Health · doi:10.1016/j.bbih.2020.100133 · Cited by 27
Rupprecht, C., Rupprecht, R., & Rammes, G. (2021) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-021-01273-9 · Cited by 22
Wißfeld, J., Assale, T. A., Cuevas-Ríos, G., Liao, H., & Neumann, H. (2024) · Frontiers in Neurology · doi:10.3389/fneur.2024.1330874 · Cited by 24
Beneficial versus Detrimental Effects of Complement–Microglial Interactions in Alzheimer’s Disease
Ayyubova, G., & Fazal, N. (2024) · Brain Sciences · doi:10.3390/brainsci14050434 · Cited by 24
“Alterations of the microglial phenotype in AD lead to the activation of inflammasome signaling and the release of excessive inflammatory cytokines, which, in turn, promotes neurotoxicity and excessive microglial synapse elimination [12,44,45].”
BackgroundInfluentialResearch Progress on the Pathogenesis, Diagnosis, and Drug Therapy of Alzheimer’s Disease
Yang, Y., & Qiu, L. (2024) · Brain Sciences · doi:10.3390/brainsci14060590 · Cited by 23
Apolipoprotein E in Alzheimer’s Disease: Focus on Synaptic Function and Therapeutic Strategy
Qu, L., Xu, S., Lan, Z., Fang, S., Xu, Y., & Zhu, X. (2024) · Molecular Neurobiology · doi:10.1007/s12035-024-04449-1 · Cited by 25
“When exposed to soluble Aβ oligomers, microglia engulf synaptic material in a complement receptor CR3-dependent pathway [70].”
What Is the Role of Cytokines in Synaptic Transmission?
Benarroch, E. E. (2024) · Neurology · doi:10.1212/wnl.0000000000209928 · Cited by 24
Sun, H., Wang, H., Wu, C., Liu, G., He, M., Zhang, H., Hou, F., & Liao, H. (2025) · Stroke · doi:10.1161/strokeaha.124.049265 · Cited by 21
Circadian rhythm, microglia-mediated neuroinflammation, and Alzheimer’s disease
Geng, F., Zhao, N., & Ren, Q. (2025) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2025.106044 · Cited by 25
Chen, Y., Qi, W., Peng, W., Fang, W., Song, G., Hao, Y., & Wang, Y. (2025) · Food Research International · doi:10.1016/j.foodres.2025.116086 · Cited by 26
Augusto‐Oliveira, M., Arrifano, G. D. P., Leal-Nazaré, C. G., Chaves-Filho, A. J. M., Santos-Sacramento, L., Lopes-Araújo, A., Tremblay, M., & Lopez, M. E. C. (2025) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2025.106091 · Cited by 31
Aged Gut Microbiota Contributes to Cognitive Impairment and Hippocampal Synapse Loss in Mice
Li, M., Ren, J., Bao, Y., Wei, W., Yu, X., He, X., gulisima, M., Sheng, L., Zheng, N., Wan, J., et al. (2025) · Aging Cell · doi:10.1111/acel.70064 · Cited by 27
“Synapse loss is an early feature in the pathophysiology of neurodegenerative diseases that precedes neuronal death and represents a significant correlate of cognitive decline (Hong et al. 2016); synaptic deficit is considered a sign of the neuronal degenerative process.”
Zhang, H., Jin, Q., Li, J., Wang, J., Li, M., Yin, Q., Li, Q., Qi, Y., Feng, L., Shen, L., et al. (2025) · PLoS Pathogens · doi:10.1371/journal.ppat.1013126 · Cited by 27
“Conversely, excessive pruning by the complement system during pathological states may result in unwarranted synaptic elimination, and this has been associated with cognitive deficits [57,75].”
Autism Spectrum Disorder: A Neuro-Immunometabolic Hypothesis of the Developmental Origins
Frasch, M. G., Yoon, B.-J., Helbing, D. L., Snir, G., Antonelli, M. C., & Bauer, R. (2023) · Biology · doi:10.3390/biology12070914 · Cited by 29
“Complement pathway C1QA Aside from their traditional role in innate immunity [42], elements of the complement pathway are involved in neuronal–glial interactions; recognized as essential players in brain development, especially in synaptogenesis/synaptic pruning and predisposition for neurodegenerative diseases [7,43]…”
BackgroundProtective role of anticancer drugs in neurodegenerative disorders: A drug repurposing approach
Advani, D., Gupta, R. V., Tripathi, R. S., Sharma, S., Ambasta, R. K., & Kumar, P. (2020) · Neurochemistry International · doi:10.1016/j.neuint.2020.104841 · Cited by 25
Wang, N., Sun, Y., Yang, H., Xu, Y., Cai, Y., Liu, T., Qin, X., Zhu, D.-F., & Wang, F. (2020) · Thyroid · doi:10.1089/thy.2020.0139 · Cited by 21
“Digital images at · 20,000 (15 images per animal) were used to evaluate postsynaptic density (PSD) (29).”
InfluentialVanDusen, K. W., Li, Y., Cai, V., Hall, A., Hiles, S., Thompson, J. W., Moseley, M. A., Cooter, M. L., Acker, L., Levy, J. H., et al. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-201544 · Cited by 22
Ciechanowska, A., Ciapała, K., Pawlik, K., Oggioni, M., Mercurio, D., Simoni, M.-G. D., & Mika, J. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms22010045 · Cited by 24
Pathways linking Alzheimer’s disease risk genes expressed highly in microglia
Hodges, A. K., Piers, T. M., Collier, D., Cousins, O., & Pocock, J. M. (2021) · Neuroimmunology and Neuroinflammation · doi:10.20517/2347-8659.2020.60 · Cited by 21
“Synaptic remodelling involving microglia is commonly found to be dependent on the activation of the complement cascade([39,41,46-48]), although not all phagocytic activities of microglia have been shown to rely”
Molecular Factors Mediating Neural Cell Plasticity Changes in Dementia Brain Diseases
Kozubski, W. P., Ong, K. T., Waleszczyk, W. J., Zabel, M. K., & Dorszewska, J. (2021) · Neural Plasticity · doi:10.1155/2021/8834645 · Cited by 23
“Chronic neuroinflammation may lead to neurodegeneration and subsequent decrease in NE levels [112].”
BackgroundWestacott, L. J., Haan, N., Evison, C., Marei, O., Hall, J., Hughes, T. R., Zaben, M., Morgan, B. P., Humby, T., Wilkinson, L. S., et al. (2021) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2021.08.215 · Cited by 25
Das, M., Mao, W., Shao, E., Tamhankar, S., Yu, G.-Q., Yu, X., Ho, K., Wang, X., Wang, J., & Mucke, L. (2021) · iScience · doi:10.1016/j.isci.2021.103245 · Cited by 21
Microglial SIRPα Deletion Facilitates Synapse Loss in Preclinical Models of Neurodegeneration
Wu, C., Yang, L., Youngblood, H. A., Liu, T. C., & Duan, R. (2021) · Neuroscience Bulletin · doi:10.1007/s12264-021-00795-5 · Cited by 21
“Although the ’’eat me’’ signal C1q is significantly elevated and contributes to synaptic loss in neurodegenerative disease [10], the role of the ‘‘don’t eat me signal’’, especially microglial SIRPa-CD47, in synapto-pathological diseases was unclear.”
BackgroundGhosh, I., Liu, C. S., Swardfager, W., Lanctôt, K. L., & Anderson, N. D. (2021) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2021.103683 · Cited by 21
Shu, J., Wei, W., & Zhang, L. (2022) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2022.751044 · Cited by 27
Qu, W., Canoll, P., & Hargus, G. (2023) · Neuroscience · doi:10.1016/j.neuroscience.2022.05.006 · Cited by 24
“, 2021), which is implicated in synapse loss in AD (Hong et al., 2016; Lian et al., 2016).”
BackgroundALZT-OP1: an experimental combination regimen for the treatment of Alzheimer’s disease
Lozupone, M., Berardino, G., Mollica, A., Sardone, R., Dibello, V., Zupo, R., Lampignano, L., Castellana, F., Bortone, I., Stallone, R., et al. (2022) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2022.2095261 · Cited by 23
“help to drive synapse degeneration [42].”
Re, G.-F., Li, H., Yang, J.-Q., Li, Y., Zhang, Z., Wu, X., Zhou, R., Kong, D., Luo, H., Kuang, Y., et al. (2022) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2022.955799 · Cited by 22
Microglia: Friends or Foes in Glaucoma? A Developmental Perspective
Ahmad, I., & Subramani, M. (2022) · Stem Cells Translational Medicine · doi:10.1093/stcltm/szac077 · Cited by 23
Deletion of PTEN in microglia ameliorates chronic neuroinflammation following repetitive mTBI
Pearson, A., Ortiz, C., Eisenbaum, M., Arrate, C., Browning, M., MULLAN, M. J., Bachmeier, C. J., Crawford, F., & Ojo, J. O. (2023) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2023.103855 · Cited by 25
Dundee, J. M., Puigdellívol, M., Butler, R., & Brown, G. C. (2023) · Journal of Neuroscience · doi:10.1523/jneurosci.1089-23.2023 · Cited by 27
Immunity impacts cognitive deficits across neurological disorders
Shaw, B. C., Anders, V., Tinkey, R. A., Habean, M. L., Brock, O. D., Frostino, B. J., & Williams, J. L. (2023) · Journal of Neurochemistry · doi:10.1111/jnc.15999 · Cited by 44
“…though there is evidence for its impact in FTLD. Complement, however, is heavily implicated in multiple disorders, including MS (Ramaglia et al., 2021 ), AD (Hong et al., 2016 ; Shi et al., 2017), FTLD (Lui et al., 2016 ), TBI (Mallah et al., 2021 disorders such as autism (Odell et al., 2005 ).”
Wang, J., Wu, S., Zhang, J., Li, Y., Wu, Y., & Qi, X. (2023) · BMC Nephrology · doi:10.1186/s12882-023-03410-z · Cited by 21
“Serum complement has also been associated with synapse loss in Alzheimer’s disease [40].”
BackgroundHotspots and trends of microglia in Alzheimer's disease: a bibliometric analysis during 2000–2022
Zhang, L., Yao, Q., Hu, J., Qiu, B., Xiao, Y., Zhang, Q., Zeng, Y., Zheng, S., Zhang, Y., Wan, Y., et al. (2024) · European journal of medical research · doi:10.1186/s40001-023-01602-9 · Cited by 24
“Two of them concentrated on how microglia affected progression of AD [32, 33], while the other three explored new pathways and novel cell subpopulations [27, 34, 35].”
BackgroundScreening Techniques for Drug Discovery in Alzheimer’s Disease
Maniam, S., & Maniam, S. (2024) · ACS Omega · doi:10.1021/acsomega.3c07046 · Cited by 24
Metadata
- Authors
- Hong, S., Beja-Glasser, V. F., Nfonoyim, B. M., Frouin, A., Li, S., Ramakrishnan, S., Merry, K. M., Shi, Q., Rosenthal, A., Barres, B. A., Lemere, C. A., Selkoe, D. J., & Stevens, B.
- Affiliations
- Boston Children's Hospital (US)
- Brigham and Women's Hospital (US)
- University of California, San Francisco (US)
- Stanford Medicine (US)
- Broad Institute (US)
- Corresponding author
- Beja-Glasser, Victoria F.
- Nfonoyim, Bianca M.
- Stevens, Beth
- ORCID
- Venue
- Science
- Published
- 2016-05-06
- Volume
- 352
- Issue
- 6286
- Pages
- 712-716
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC5094372
- OpenAlex
- W2314634699
- Cited by
- 3,343
- References
- 33
- Citations by year
- 2026: 415 · 2025: 391 · 2024: 384 · 2023: 388 · 2022: 324 · 2021: 363 · 2020: 306 · 2019: 260 · 2018: 240 · 2017: 198 · 2016: 69
- FWCI
- 140.04
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Edward R. and Anne G. Lefler Fellowship
- Coins for Alzheimer's Research Trust
- Fidelity Biosciences Research Initiative
- JPB Foundation
- National Institutes of Health (AG000222)
- National Institute of Neurological Disorders and Stroke-NIH (R01NS083845)
- National Institute on Aging-NIH (1RF1AG051496A)
- Topics
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Keywords
- Alzheimer's disease, synaptic loss, complement system, microglia, C1q, CR3, complement C3, soluble amyloid-beta oligomers, neuroinflammation, synaptic pruning, hippocampal long-term potentiation, phagocytosis, mouse model
- MeSH terms
- Disks Large Homolog 4 Protein, Alzheimer Disease, Animals, Cognition Disorders, Complement Pathway, Classical, Disease Models, Animal, Membrane Proteins, Phagocytosis, Synapses, Up-Regulation, Complement C1q, Macrophage-1 Antigen, Amyloid beta-Peptides, Synaptophysin, Microglia, Long-Term Potentiation, Mice, Knockout, Mice, Guanylate Kinases, CA1 Region, Hippocampal, Plaque, Amyloid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.